Rilemo’s commercial model is designed to combine upfront device sales with recurring software and service revenues, creating both initial hardware value capture and a growing installed-base revenue stream over time.
Rilemo is being developed as a portable low-power microwave neuro-imaging device designed to provide rapid point-of-care anatomical information in cerebrovascular care settings, complementing standard imaging modalities such as CT and MRI.
This positioning supports a business model and pricing logic closer to an accessible portable neuro-imaging platform than to standard bedside monitors or non-imaging neuro-triage tools.
Clinical and economic value
Rilemo’s value proposition is grounded in its ability to bring brain imaging-derived information closer to the patient, in settings where access to conventional imaging may be delayed, logistically complex, or less compatible with unstable patients.
In this context, the platform is designed to create value through:
- faster access to anatomical information at the point of care;
- support for earlier triage and clinical decision-making;
- reduced need to move unstable patients to radiology;
- improved workflow efficiency across emergency, neurological, and critical-care pathways;
- more accessible imaging support in environments where CT and MRI remain essential but not always immediately available.
Beyond its direct clinical value, Rilemo may also contribute to a more efficient use of existing imaging infrastructure. By providing earlier bedside support, the platform can help reduce pressure on urgent CT and MRI workflows, improve the prioritization of available imaging capacity, and enhance the overall utilization of high-cost diagnostic resources.
From an economic perspective, the main value drivers of a portable neuro-imaging platform include fewer repeat CT/MRI scans, reduced inter-hospital transfers of unstable patients, and shorter ICU or high-dependency stays. In this context, conventional imaging exams may already represent several hundred EUR/USD per scan, while ICU daily costs in European settings are often in the order of ~€1,200-2,000 per day. Based on analogous technologies and pathway-level assumptions, this makes it plausible for mid-volume sites to recover the investment in a mid-five-figure to low-six-figure system within roughly two years, provided that the device delivers measurable improvements in their clinical workflow and decision pathway.
Market positioning and pricing logic
Rilemo is positioned between baseline bedside tools and advanced portable and mobile neuro-imaging systems.
At the lower end of the benchmark sit non-imaging neuro-triage tools, ICU monitoring platforms, and high-spec portable ultrasound systems, which typically range in the mid-five-figure range but do not provide dedicated brain imaging.
At the upper end sit portable neuro-imaging and mobile imaging solutions, such as portable MRI, mobile CT, and stroke-unit-based imaging systems, which command significantly higher pricing and operational complexity.
Within this landscape, Rilemo is designed to occupy a distinct middle position: offering brain-specific, imaging-derived information in a format that is substantially more portable, accessible, and workflow-compatible than advanced mobile imaging systems. At the same time, it delivers greater specificity and imaging value than conventional monitoring or non-imaging triage devices.
Based on this positioning, Rilemo’s pricing logic is more consistent with a diagnostic portable neuro-imaging corridor than with a conventional monitoring-device price anchor. Internal pricing work supports a reference range in the order of €70k-120k CAPEX-equivalent per device, positioning Rilemo:
- above non-imaging triage systems and standard bedside equipment, reflecting the added value of brain imaging;
- below more mature and higher-cost portable MRI and mobile CT solutions, consistent with Rilemo’s focus on accessible portability and its current stage of market development.
This positioning also preserves pricing headroom for future premium configurations as evidence, certification, software functionality, and adoption continue to mature.
Detailed benchmarking across adjacent bedside tools, neuro-triage systems, and portable neuro-imaging solutions is here provided:
Business Model
Rilemo’s business model is built on two core revenue components:
Hardware Sales
An upfront CAPEX payment for the imaging device, reflecting the value of portable point-of-care neuro-imaging hardware.
Recurring Software & Service Revenues
An annual recurring fee covering access to the software environment, AI-enabled functionality, product updates, technical support, and service-related activities required to keep the system clinically and operationally effective over time.
Medical devices are commercialized as a 5-year bundle combining upfront hardware purchase with annual software fees. Upon expiry, the software contract renews automatically, with potential for tariff step-up aligned with product maturity and installed-base growth.
This structure combines upfront CAPEX revenues with recurring software and service fees, aligning revenue generation with both initial device adoption and the long-term value of the installed base, while supporting continuous product improvement and scalable deployment.
Initial commercial assumptions
For financial planning purposes (
Financial Plan), Rilemo is currently adopting a conservative base-case assumption of:
Hardware price: €50k per device
Annual recurring software & service revenues: €10k per installed system
These assumptions are intentionally prudent and reflect an early commercialization approach designed to support credible financial planning and facilitate initial market adoption.
Long-term pricing potential
While Rilemo’s current financial model is built on a conservative base case, the company believes the platform carries meaningful upside potential over time.
Internal pricing work and market benchmarking indicate that a portable brain-imaging platform with Rilemo’s positioning may support a value corridor above the current entry assumptions, particularly as the company progresses on clinical evidence generation, regulatory milestones, workflow integration, and software / AI-enabled capabilities.
In Europe, this longer-term potential remains broadly consistent with a diagnostic portable neuro-imaging corridor in the order of €70k-120k CAPEX-equivalent per device, combined with recurring annual software and service revenues. In the United States, the equivalent strategic positioning may support ~$100k-150k CAPEX-equivalent per device, while commercial deployment may progressively evolve toward tiered subscription-based structures, reflecting the stronger relevance of service-oriented models in that market.
In parallel, the recurring fee structure is designed to evolve progressively as the platform matures. The initial annual tier will expand to include AI-enabled diagnostic modules, advanced software functionality, and broader clinical capabilities, supporting a pathway toward a tiered recurring revenue model that reflects the increasing value delivered to clinical users over time. This evolution is expected to contribute meaningfully to the long-term revenue profile of the installed base, without requiring aggressive assumptions at the current stage of commercialization.
As further described in the 
Go-to-Market and 
Regulatory Pathway sections, pricing evolution will be linked to the company’s certification path, commercial model development, and market adoption across its target settings.
Health Economic ReferencesCost of CT / imaging and on‑site CT vs external CT:
- Economic Evaluation of On‑Site CT in Germany (costs per CT‑indicated patient, 220–243 EUR vs 908 EUR)
- Private CT scan cost in the UK (300–800+ GBP)
ICU daily cost and impact of LOS:
- Microcosting ICU costs in three European countries (1,225–1,911 EUR/day)
Transfer‑related costs:
- Effect of inter‑hospital transfer on resource utilization and hospital costs (~9,600 USD higher per ICU admission)
Analogous neuromonitoring/imaging economics:
- Cerebral oximetry (INVOS) cost analysis in cardiac surgery (~£102,000 net savings per 100 patients)
- Potential application of ultra‑low‑field portable MRI in ICU (throughput and cost implications)
- Swoop Portable MRI clinical and business case (outpatient capacity, ICU benefits)
This Data Room is provided to you by:
Rilemo S.r.l.
Via Don Sebastiano Colleoni 20, Robbiate (LC), 23899, Italy
EU VAT: IT 04187140134 - ATECO: 26.60.02
PEC: rilemo@legalmail.it
Made with Bullet